HCV transmission in industrialized countries and resource-constrained areas

Nature Reviews Gastroenterology and Hepatology

Volumn 11, Issue 1, 2014, Pages 28-35

  Thursz, Mark ^a   Fontanet, Arnaud ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACUPUNCTURE; ANTIBODY SCREENING; AWARENESS; BLOOD TRANSFUSION; BODY FLUID; DRUG COST; HARM REDUCTION; HEALTH CARE PERSONNEL; HEALTH EDUCATION; HEPATITIS C; HUMAN; INDUSTRIALIZATION; INFECTION RISK; MEDICAL PROCEDURES; NEEDLESTICK INJURY; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; RISK FACTOR; SEXUAL TRANSMISSION; TATTOOING; VERTICAL TRANSMISSION; VIRUS TRANSMISSION;

ANTIVIRAL AGENTS; BLOOD TRANSFUSION; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; DRUG COSTS; HEALTH SERVICES ACCESSIBILITY; HEPACIVIRUS; HEPATITIS C; HUMANS; IATROGENIC DISEASE; PREVALENCE; RISK FACTORS;

EID: 84891738607     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2013.179     Document Type: Review

References (131)

1. Alter, H. J. et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N. Engl. J. Med. 321, 1494-1500 (1989)
2. Perz, J. F., Armstrong, G. L., Farrington, L. A., Hutin, Y. J. & Bell, B. P. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J. Hepatol. 45, 529-538 (2006)
3. Lavanchy, D. Evolving epidemiology of hepatitis C virus. Clin. Microbiol. Infect. 17, 107-115 (2011)
4. Kim, W. R. et al. Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. Gastroenterology 137, 1680-1686 (2009)
5. Alter, M. J. Prevention of spread of hepatitis C. Hepatology 36, S93-S98 (2002)
6. Farci, P. et al. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc. Natl Acad. Sci. USA 91, 7792-7796 (1994)
7. Simmonds, P. The origin and evolution of hepatitis viruses in humans. J. Gen. Virol. 82, 693-712 (2001)
8. Simmonds, P. et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42, 962-973 (2005)
9. Pybus, O. G. et al. The epidemic behavior of the hepatitis C virus. Science 292, 2323-2325 (2001)
10. Magiorkinis, G. et al. The global spread of hepatitis C virus 1a and 1b: a phylodynamic and phylogeographic analysis. PLoS Med. 6, e1000198 (2009)
11. Alter, H. J. Transfusion transmitted hepatitis C and non-A, non-B, non-C. Vox Sang. 67 (Suppl. 3), 19-24 (1994)
12. Prati, D. Transmission of hepatitis C virus by blood transfusions and other medical procedures: a global review. J. Hepatol. 45, 607-616 (2006)
13. Alvarez, M., Oyonarte, S., Rodriguez, P. M. & Hernandez, J. M. Estimated risk of transfusion-Transmitted viral infections in Spain. Transfusion 42, 994-998 (2002)
14. Quer, J. & Esteban, J. in Viral Hepatitis (eds Thomas, H. C., Lemon, S. & Zuckerman, A. J.) 407-425 (Blackwell, 2005)
15. Lee, S. R. et al. Increased detection of hepatitis C virus infection in commercial plasma donors by a third-generation screening assay. Transfusion 35, 845-849 (1995)
16. Conry-Cantilena, C. et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N. Engl. J. Med. 334, 1691-1696 (1996)
17. Kenny-Walsh, E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N. Engl. J. Med. 340, 1228-1233 (1999)
18. Wiese, M. et al. Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany-A 25-year multicenter study. J. Hepatol. 43, 590-598 (2005)
19. Makris, M. et al. Hepatitis C antibody and chronic liver disease in haemophilia. Lancet 335, 1117-1119 (1990)
20. Kleinman, S. et al. Increased detection of hepatitis C virus (HCV)-infected blood donors by a multiple-Antigen HCV enzyme immunoassay. Transfusion 32, 805-813 (1992)
21. Pawlotsky, J. M. et al. What strategy should be used for diagnosis of hepatitis C virus infection in clinical laboratories? Hepatology 27, 1700-1702 (1998)
22. Velati, C. et al. Residual risk of transfusion-Transmitted HCV and HIV infections by antibody-screened blood in Italy. Transfusion 42, 989-993 (2002)
23. Dodd, R. Y., Notari, E. P. & Stramer, S. L. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 42, 975-979 (2002)
24. Netski, D. M. et al. Humoral immune response in acute hepatitis C virus infection. Clin. Infect. Dis. 41, 667-675 (2005)
25. Tagny, C. T., Mbanya, D., Tapko, J. B. & Lefrere, J. J. Blood safety in Sub-Saharan Africa: a multi-factorial problem. Transfusion 48, 1256-1261 (2008)
26. World Health Organisation. Global Database on Blood Safety Reports 2011 [online], http://www.who.int/bloodsafety/global-database/GDBS-Summary-Report- 2011.pdf (2011)
27. Laperche, S. Multinational assessment of blood-borne virus testing and transfusion safety on the African continent. Transfusion 53, 816-826 (2012)
28. Luby, S. et al. Evaluation of blood bank practices in Karachi, Pakistan, and the governments response. J. Pak. Med. Assoc. 56, S25-S30 (2006)
29. Widell, A. et al. Detection of hepatitis C core antigen in serum or plasma as a marker of hepatitis C viraemia in the serological window-phase. Transfus. Med. 12, 107-113 (2002)
30. Beer, N. et al. Accuracy of hepatitis C virus core antigen testing in pools among seroconverters. Transfusion 46, 1822-1828 (2006)
31. Laperche, S. et al. Is an assay for simultaneous detection of hepatitis C virus core antigen and antibody a valuable alternative to nucleic acid testing? Transfusion 45, 1965-1972 (2005)
32. Yuksel, P. et al. New approaches to in vitro diagnosis of hepatitis C infection a reason for post transfusion hepatitis: Diagnostic value of determination of hepatitis C virus core antigen. Transfus. Apher. Sci. 45, 247-250 (2011)
33. Sanchez-Tapias, J. M. Nosocomial transmission of hepatitis C virus. J. Hepatol. 31 (Suppl. 1), 107-112 (1999)
34. Krause, G. et al. Nosocomial transmission of hepatitis C virus associated with the use of multidose saline vials. Infect. Control Hosp. Epidemiol. 24, 122-127 (2003)
35. Desenclos, J. C. et al. Hepatitis C in a ward for cystic fibrosis and diabetic patients: possible transmission by spring-loaded finger-stick devices for self-monitoring of capillary blood glucose. Infect. Control Hosp. Epidemiol. 22, 701-707 (2001)
36. Massari, M. et al. Transmission of hepatitis C virus in a gynecological surgery setting. J. Clin. Microbiol. 39, 2860-2863 (2001)
37. Bronowicki, J. P. et al. Patient-To-patient transmission of hepatitis C virus during colonoscopy. N. Engl. J. Med. 337, 237-240 (1997)
38. Patel, P. R. et al. Hepatitis C virus infections from a contaminated radiopharmaceutical used in myocardial perfusion studies. JAMA 296, 2005-2011 (2006)
39. Fischer, G. E. et al. Hepatitis C virus infections from unsafe injection practices at an endoscopy clinic in Las Vegas, Nevada, 2007-2008. Clin. Infect. Dis. 51, 267-273 (2010)
40. Gutelius, B. et al. Multiple clusters of hepatitis virus infections associated with anesthesia for outpatient endoscopy procedures. Gastroenterology 139, 163-170 (2010)
41. Esteban, J. I. et al. Transmission of hepatitis C virus by a cardiac surgeon. N. Engl. J. Med. 334, 555-560 (1996)
42. Thompson, N. D., Perz, J. F., Moorman, A. C. & Holmberg, S. D. Nonhospital health care-Associated hepatitis B and C virus transmission: United States, 1998-2008. Ann. Intern. Med. 150, 33-39 (2009)
43. DeMaria, A., Jr & Snydman, D. R. Nosocomial hepatitis C: more of a hidden epidemic. Ann. Intern. Med. 156, 534-535 (2012)
44. Chlabicz, S., Grzeszczuk, A. & Prokopowicz, D. Medical procedures and the risk of iatrogenic hepatitis C infection: case-controlled study in north-eastern Poland. J. Hosp. Infect. 58, 204-209 (2004)
45. Guerra, J., Garenne, M., Mohamed, M. K. & Fontanet, A. HCV burden of infection in Egypt: results from a nationwide survey. J. Viral Hepat. 19, 560-567 (2012)
46. Frank, C. et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 355, 887-891 (2000)
47. Nerrienet, E. et al. Hepatitis C virus infection in Cameroon: A cohort-effect. J. Med. Virol. 76, 208-214 (2005)
48. Njouom, R. et al. Phylogeography, risk factors and genetic history of hepatitis C virus in Gabon, central Africa. PLoS ONE 7, e42002 (2012)
49. Iles, J. C. et al. Hepatitis C virus infections in the Democratic Republic of Congo exhibit a cohort effect. Infect. Genet. Evol. http://dx.doi.org/10.1016/j.meegid.2013.01.021.
50. Breban, R. et al. Towards realistic estimates of HCV incidence in Egypt. J. Viral Hepat. 20, 294-296 (2013)
51. Paez, J. A. et al. HCV iatrogenic and intrafamilial transmission in Greater Cairo, Egypt. Gut 59, 1554-1560 (2010)
52. Pepin, J. et al. Iatrogenic transmission of human T cell lymphotropic virus type 1 and hepatitis C virus through parenteral treatment and chemoprophylaxis of sleeping sickness in colonial Equatorial Africa. Clin. Infect. Dis. 51, 777-784 (2010)
53. Pepin, J. et al. Risk factors for hepatitis C virus transmission in colonial Cameroon. Clin. Infect. Dis. 51, 768-776 (2010)
54. Simonsen, L., Kane, A., Lloyd, J., Zaffran, M. & Kane, M. Unsafe injections in the developing world and transmission of bloodborne pathogens: a review. Bull. World Health Organ. 77, 789-800 (1999)
55. Hutin, Y. J., Hauri, A. M. & Armstrong, G. L. Use of injections in healthcare settings worldwide, 2000: literature review and regional estimates. BMJ 327, 1075 (2003)
56. Kermode, M. Unsafe injections in low-income country health settings: need for injection safety promotion to prevent the spread of blood-borne viruses. Health Promot. Int. 19, 95-103 (2004)
57. Logez, S., Hutin, Y., Somda, P., Thuault, J. & Holloway, K. Safer injections following a new national medicine policy in the public sector, Burkina Faso 1995-2000. BMC Public Health 5, 136 (2005)
58. Mathers, B. M. et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 372, 1733-1745 (2008)
59. Quan, V. M. et al. Risks for HIV, HBV, and HCV infections among male injection drug users in northern Vietnam: a case-control study. AIDS Care 21, 7-16 (2009)
60. Nelson, P. K. et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 378, 571-583 (2011)
61. Roy, K. et al. Monitoring hepatitis C virus infection among injecting drug users in the European Union: a review of the literature. Epidemiol. Infect. 129, 577-585 (2002)
62. Hahn, J. A. et al. Hepatitis C virus seroconversion among young injection drug users: relationships and risks. J. Infect. Dis. 186, 1558-1564 (2002)
63. Hagan, H., Pouget, E. R. & Des Jarlais, D. C. A systematic review and meta-Analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. J. Infect. Dis. 204, 74-83 (2011)
64. Hagan, H., Pouget, E. R., Des Jarlais, D. C. & Lelutiu-Weinberger, C. Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place. Am. J. Epidemiol. 168, 1099-1109 (2008)
65. Scheinmann, R. et al. Non-injection drug use and hepatitis C virus: a systematic review. Drug Alcohol Depend. 89, 1-12 (2007)
66. Turner, K. M. et al. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction 106, 1978-1988 (2011)
67. Martin, N. K. et al. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J. Hepatol. 54, 1137-1144 (2011)
68. Martin, N. K. et al. Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology 55, 49-57 (2012)
69. Martin, N. K. et al. Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-Acting antivirals. Hepatology . http://dx.doi.org/10.1002/hep.26431
70. Wilkinson, M. et al. Community-based treatment for chronic hepatitis C in drug users: high rates of compliance with therapy despite ongoing drug use. Aliment. Pharmacol. Ther. 29, 29-37 (2009)
71. Hellard, M., Sacks-Davis, R. & Gold, J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin. Infect. Dis. 49, 561-573 (2009)
72. Tohme, R. A. & Holmberg, S. D. Is sexual contact a major mode of hepatitis C virus transmission? Hepatology 52, 1497-1505 (2010)
73. Farias, A. et al. Detection of hepatitis C virus (HCV) in body fluids from HCV monoinfected and HCV/HIV coinfected patients. Hepatogastroenterology 57, 300-304 (2010)
74. Leruez-Ville, M., Kunstmann, J. M., De, A. M., Rouzioux, C. & Chaix, M. L. Detection of hepatitis C virus in the semen of infected men. Lancet 356, 42-43 (2000)
75. Debono, E. et al. Absence of hepatitis C genome in semen of infected men by polymerase chain reaction, branched DNA and in situ hybridization. Liver 20, 257-261 (2000)
76. Chayama, K. et al. Molecular analysis of intraspousal transmission of hepatitis C virus. J. Hepatol. 22, 431-439 (1995)
77. Thomas, D. L. et al. Sexual transmission of hepatitis C virus among patients attending sexually transmitted diseases clinics in Baltimore-An analysis of 309 sex partnerships. J. Infect. Dis. 171, 768-775 (1995)
78. Meisel, H. et al. Transmission of hepatitis C virus to children and husbands by women infected with contaminated anti-D immunoglobulin. Lancet 345, 1209-1211 (1995)
79. Kao, J. H. et al. Low incidence of hepatitis C virus transmission between spouses: a prospective study. J. Gastroenterol. Hepatol. 15, 391-395 (2000)
80. Marincovich, B. et al. Absence of hepatitis C virus transmission in a prospective cohort of heterosexual serodiscordant couples. Sex. Transm. Infect. 79, 160-162 (2003)
81. Vandelli, C. et al. Lack of evidence of sexual transmission of hepatitis C among monogamous couples: results of a 10-year prospective follow-up study. Am. J. Gastroenterol. 99, 855-859 (2004)
82. Salleras, L. et al. Importance of sexual transmission of hepatitis C virus in seropositive pregnant women: a case-control study. J. Med. Virol. 52, 164-167 (1997)
83. Wang, C. C. et al. Acute hepatitis C in a contemporary US cohort: modes of acquisition and factors influencing viral clearance. J. Infect. Dis. 196, 1474-1482 (2007)
84. Marx, M. A. et al. Association of hepatitis C virus infection with sexual exposure in southern India. Clin. Infect. Dis. 37, 514-520 (2003)
85. Terrault, N. A. et al. Sexual transmission of HCV among monogamous heterosexual couples: The HCV partners study. Hepatology 57, 881-889 (2012)
86. Morin, T. et al. Acute hepatitis C: analysis of a 126-case prospective, multicenter cohort. Eur. J. Gastroenterol. Hepatol. 22, 157-166 (2010)
87. Urbanus, A. T. et al. Hepatitis C virus infections among HIV-infected men who have sex with men: an expanding epidemic. AIDS 23, F1-F7 (2009)
88. Giraudon, I. et al. Increase in diagnosed newly acquired hepatitis C in HIV-positive men who have sex with men across London and Brighton, 2002-2006: is this an outbreak? Sex. Transm. Infect. 84, 111-115 (2008)
89. Fierer, D. S. et al. Liver fibrosis during an outbreak of acute hepatitis C virus infection in HIV-infected men: a prospective cohort study. J. Infect. Dis. 198, 683-686 (2008)
90. Taylor, L. E. et al. Incident hepatitis C virus infection among US HIV-infected men enrolled in clinical trials. Clin. Infect. Dis. 52, 812-818 (2011)
91. Matthews, G. V., Hellard, M., Kaldor, J., Lloyd, A. & Dore, G. J. Further evidence of HCV sexual transmission among HIV-positive men who have sex with men: response to Danta. et al. AIDS 21, 2112-2113 (2007)
92. Yaphe, S. et al. Incidence of acute hepatitis C virus infection among men who have sex with men with and without HIV infection: a systematic review. Sex. Transm. Infect. 88, 558-564 (2012)
93. van de Laar, T. J., Matthews, G. V., Prins, M. & Danta, M. Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection. AIDS 24, 1799-1812 (2010)
94. Roudot-Thoraval, F. et al. Lack of mother-To-infant transmission of hepatitis C virus in human immunodeficiency virus-seronegative women: a prospective study with hepatitis C virus RNA testing. Hepatology 17, 772-777 (1993)
95. Ohto, H. et al. Transmission of hepatitis C virus from mothers to infants. The Vertical Transmission of Hepatitis C Virus Collaborative Study Group. N. Engl. J. Med. 330, 744-750 (1994)
96. Roberts, E. A. & Yeung, L. Maternal-infant transmission of hepatitis C virus infection. Hepatology 36 (Suppl. 1), S106-S113 (2002)
97. Yeung, L. T., King, S. M. & Roberts, E. A. Mother-To-infant transmission of hepatitis C virus. Hepatology 34, 223-229 (2001)
98. Arshad, M., El-Kamary, S. S. & Jhaveri, R. Hepatitis C virus infection during pregnancy and the newborn period-Are they opportunities for treatment? J. Viral Hepat. 18, 229-236 (2011)
99. Davison, S. M., Mieli-Vergani, G., Sira, J. & Kelly, D. A. Perinatal hepatitis C virus infection: diagnosis and management. Arch. Dis. Child. 91, 781-785 (2006)
100. Ghamar Chehreh, M. E., Tabatabaei, S. V., Khazanehdari, S. & Alavian, S. M. Effect of cesarean section on the risk of perinatal transmission of hepatitis C virus from HCV-RNA+/HIV - mothers: a meta-Analysis. Arch. Gynecol. Obstet. 283, 255-260 (2011)
101. Cottrell, E. B., Chou, R., Wasson, N., Rahman, B. & Guise, J. M. Reducing risk for mother-To-infant transmission of hepatitis C virus: a systematic review for the U. S. Preventive Services Task Force. Ann. Intern. Med. 158, 109-113 (2013)
102. European Paediatric Hepatitis C Virus Network. Effects of mode of delivery and infant feeding on the risk of mother-To-child transmission of hepatitis C virus. European Paediatric Hepatitis C Virus Network. BJOG 108, 371-377 (2001)
103. Henderson, D. K. Management of needlestick injuries: a house officer who has a needlestick. JAMA 307, 75-84 (2012)
104. Nienhaus, A., Kesavachandran, C., Wendeler, D., Haamann, F. & Dulon, M. Infectious diseases in healthcare workers-An analysis of the standardised data set of a German compensation board. J. Occup. Med. Toxicol. 7, 8-7 (2012)
105. Jagger, J., Puro, V. & De, C. G. Occupational transmission of hepatitis C virus. JAMA 288, 1469-1471 (2002)
106. Puro, V., Petrosillo, N. & Ippolito, G. Risk of hepatitis C seroconversion after occupational exposures in health care workers. Italian Study Group on Occupational Risk of HIV and Other Bloodborne Infections. Am. J. Infect. Control. 23, 273-277 (1995)
107. Tomkins, S. E. et al. Occupational transmission of hepatitis C in healthcare workers and factors associated with seroconversion: UK surveillance data. J. Viral Hepat. 19, 199-204 (2012)
108. Yazdanpanah, Y. et al. Risk factors for hepatitis C virus transmission to health care workers after occupational exposure: a European case-control study. Clin. Infect. Dis. 41, 1423-1430 (2005)
109. Rosen, H. R. Acquisition of hepatitis C by a conjunctival splash. Am. J. Infect. Control. 25, 242-247 (1997)
110. Deuffic-Burban, S. et al. Immediate vs. delayed treatment in patients with acute hepatitis C based on IL28B polymorphism: a model-based analysis. J. Hepatol. 57, 260-266 (2012)
111. Corey, K. E. et al. Pilot study of postexposure prophylaxis for hepatitis C virus in healthcare workers. Infect. Control Hosp. Epidemiol. 30, 1000-1005 (2009)
112. Tohme, R. A. & Holmberg, S. D. Transmission of hepatitis C virus infection through tattooing and piercing: a critical review. Clin. Infect. Dis. 54, 1167-1178 (2012)
113. Munier, A. et al. Frequent transient hepatitis C viremia without seroconversion among healthcare workers in Cairo, Egypt. PLoS ONE 8, e57835 (2013)
114. Knapp, S. et al. A polymorphism in IL28B distinguishes exposed, uninfected individuals from spontaneous resolvers of HCV infection. Gastroenterology 141, 320-325 (2011)
115. World Health Organisation. 63rd World Health Assembly. WHA63.18: viral hepatitis [online], http://apps.who.int/gb/ebwha/pdf-files/WHA63-REC1/WHA63- REC1-en.pdf (2010)
116. World Health Organisation. Prevention and control of viral hepatitis infection: framework for global action [online], http://www.who.int/csr/disease/ hepatitis/GHP-framework.pdf (2012)
117. Dabbouseh, N. M. & Jensen, D. M. Future therapies for chronic hepatitis C. Nat. Rev. Gastroenterol. Hepatol. 10, 268-276 (2013)
118. Smith, B. D. et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm. Rep. 61, 1-32 (2012)
119. US Department of Health and Human Services. Combating the silent epidemic of viral hepatitis: action plan for the prevention, care, and treatment of viral hepatitis [online], http://www.hhs.gov/ash/initiatives/hepatitis (2011)
120. Maher, L. Tackling hepatitis C in Australia: the third national strategy. Lancet Infect. Dis. 12, 172-173 (2012)
121. Morris, K. Tackling hepatitis C: a tale of two countries. Lancet 377, 1227-1228 (2011)
122. Health Consumer Powerhouse. Euro Hepatitis Index 2012 report [online], http://www.healthpowerhouse.com/files/euro-hepatitis-index-2012/ Report-Hepl-HCP-121104-2-w-Cover.pdf (2012)
123. Lettmeier, B. et al. Market uptake of new antiviral drugs for the treatment of hepatitis C. J. Hepatol. 49, 528-536 (2008)
124. Paez, J. A. et al. Injection drug use is a risk factor for HCV infection in urban Egypt. PLoS ONE 4, e7193 (2009)
125. Ford, N. et al. Expanding access to treatment for hepatitis C in resource-limited settings: lessons from HIV/AIDS. Clin. Infect. Dis. 54, 1465-1472 (2012)
126. Ford, N. et al. Chronic hepatitis C treatment outcomes in low- and middle-income countries: a systematic review and meta-Analysis. Bull. World Health Organ. 90, 540-550 (2012)
127. Progress toward prevention and control of hepatitis C virus infection-Egypt, 2001-2012. MMWR Morb. Mortal. Wkly Rep. 61, 545-549 (2012)
128. Swadling, L., Klenerman, P. & Barnes, E. Ever closer to a prophylactic vaccine for HCV. Expert Opin. Biol. Ther. 13, 1109-1124 (2013)
129. Urbani, S. et al. Outcome of acute hepatitis C is related to virus-specific CD4 function and maturation of antiviral memory CD8 responses. Hepatology 44, 126-139 (2006)
130. Logvinoff, C. et al. Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc. Natl Acad. Sci. USA 101, 10149-10154 (2004)
131. von, H. T. et al. Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology 132, 667-678 (2007)